Calliditas Therapeutics Q2 2024 GAAP EPS $(0.17) Misses $(0.13) Estimate, Sales $52.351M Beat $42.952M Estimate
Author: Benzinga Newsdesk | August 13, 2024 01:40am
Calliditas Therapeutics (NASDAQ:
CALT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 26.92 percent. This is a 49.23 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $52.351 million which beat the analyst consensus estimate of $42.952 million by 21.88 percent. This is a 104.45 percent increase over sales of $25.606 million the same period last year.
Posted In: CALT